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Abstract
Depressive symptoms are highly prevalent and are associated with considerable functional 
impairment, significant public health costs, and heightened mortality risk. Individuals 
experiencing impairment due to depressive symptomatology are most likely to report their 
symptoms to a primary care provider. As such, national guidelines highlight the need to assess and 
effectively treat depression via primary care. Despite these guidelines, the dissemination of 
evidence-based psychotherapy via primary care is limited, likely due to both provider- and patient-
level treatment barriers. Mobile health (mHealth) technologies are promising for addressing these 
barriers and for promoting uptake of evidence-based depression treatment. Among evidence-based 
psychotherapies for depression, brief Behavioral Activation Treatment for Depression (BATD) has 
shown great promise and is particularly amenable to mHealth delivery. Herein, we discuss the 
development of a BATD mobile application, Moodivate, that was developed in order to 
disseminate BATD via primary care. This paper focuses on description of (1) rationale for 
Moodivate treatment development, (2) Moodivate treatment components, (3) ongoing clinical trial 
evaluation of Moodivate, and (4) clinical considerations for incorporating Moodivate into clinical 
practice.
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Introduction
Depression is a leading cause of disability worldwide1 and a major contributor to the overall 
global burden of disease.2 Individuals with depressive symptomatology experience 
significant suffering, high morbidity and mortality, and considerable social and occupational 
impairment.3 Depression produces greater decrements in overall health than many other 
chronic diseases, including angina, arthritis, asthma, and diabetes.4 Thus, the need for the 
efficient and effective identification and treatment of depression is of great public health 
importance.
Many national medical organizations (United States Preventive Services Task Force, 
American Academy of Family Physicians, American College of Preventive Medicine) 
recommend screening for depression in general adult populations within primary care 
settings.5 Despite these recommendations, depression has historically been underdiagnosed 
and undertreated in primary care,3,6 resulting in negative outcomes for patients including 
prolonged depressive episodes, decreased incidence of recovery, and heightened functional 
impairment and suffering.7 As such, dissemination of evidence-based treatments for 
depressive symptomatology via primary care is critical.
Antidepressant medications are the most commonly prescribed class of medications in the 
United States8 and are a first-line treatment for depression in primary care.9 Although often 
administered as a monotherapy, research indicates significant improvement in treatment 
effect size when antidepressant medications are administered in combination with evidence-
based psychotherapy.10 Thus, promotion of evidence-based psychotherapy via primary care 
has the potential to impact depression outcomes for adult patients in primary care. However, 
there a number of barriers to this approach. From a provider standpoint, primary care 
physicians are traditionally not trained in the delivery of evidence-based psychotherapies for 
depression and typically do not have the time within their schedules for training in or 
delivery of such treatments. Referrals to mental health specialists are often unsuccessful 
with access and referral rates commonly less than 50%.11 From a patient perspective, 
barriers to traditional in person psychotherapy can include problems of transportation, child 
care, lack of time, stigma associated with mental health treatment, and lack of available 
services.12,13
Mobile health (mHealth) technologies offer an ideal strategy to overcome these barriers and 
to further disseminate effective treatment for depression. mHealth technologies are 
promising for improving the health-care environment, delivering better patient outcomes, 
and substantially lowering treatment costs.14 Several computerized psychological 
interventions for psychological depression treatment via primary care have previously been 
developed and have demonstrated success.15,16 However, mobile technologies, such as 
smartphones and mobile apps, may be superior treatment delivery platforms as they allow 
patients to have access to treatment materials at all times while also eliminating barriers to 
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computerized treatment (e.g., the need to have a computer at home or go to a primary care 
clinic to access the treatment). Smartphones have dramatically increased in both 
affordability and ubiquity in recent years, with 2017 estimates suggesting 77% of U.S. adults 
own a smartphone and the majority download apps.17,18 Moreover, the majority of 
physicians report utilizing mobile apps in their clinical practices.19
Numerous mobile apps have been developed for both commercial and research purposes 
with the goal of targeting depressive symptoms. However, many of these publically available 
apps have received criticism due to lack of clear adherence to evidence-based approaches 
and limited efficacy/effectiveness studies.20,21 Apps developed for research purposes are 
often not accessible to the general public and, thus, are not ideal for mental health treatment 
in the real world, via primary care.22 Research examining the efficacy and effectiveness of 
some publically available app treatments is beginning to grow, though to our knowledge, 
these extant mobile apps have not yet been tested within primary care. Arean et al.23 
recently completed a large (n=626), fully remote, randomized clinical trial in which 
participants with mild to moderate depression were randomized to receive one of two 
publically available depression treatment apps (Project: EVO and iPST) or a control app 
(Health Tips). Results indicated that 45% of participants randomized to Project: EVO and 
46% of participants randomized to iPST demonstrated symptom improvement over time, as 
compared to 34% of those randomized to the control condition. Further, Mohr et al.24 
developed and clinically tested a publically available suite of mobile apps called Intellicare 
for the treatment of depression and anxiety symptoms. Participants with elevated symptoms 
of anxiety or depression were followed for eight weeks as they used the Intellicare suite. 
Study outcomes were encouraging as participants utilized the apps on average 195.4 times 
over the eight-week period and had significant improvements in depressive and anxiety 
symptoms over time.24 Moreover, in the first year of public availability, 5,210 individuals 
downloaded at least one Intellicare app, suggesting widespread interest in apps for the 
treatment of depression and anxiety symptoms.22
Thus, a logical next step is to extend development and testing of publically available 
evidence-based psychological depression treatment apps to primary care. Among evidence-
based psychotherapies for depression, brief Behavioral Activation Treatment for Depression 
(BATD25,26) has shown great promise and is particularly amenable to mHealth delivery. 
BATD is grounded in behavioral principles, which suggest that depression is caused by a 
lack of reinforcement in the environment for positive, nondepressed behaviors. Thus, the 
goal of BATD is to help the patient identify, schedule, and reengage in positive activities. 
BATD accomplishes this goal by utilizing the following four treatment components, 
typically delivered across 5 to 10 treatment sessions: (1) Psychoeducation: Introduction to 
the BATD model; (2) Identification of life areas, values, and associated activities: 
Identification of values and goals within a variety of life areas important to the patient, 
including relationships, education, career, recreation, and health; (3) Daily monitoring and 
activity planning: Selection of activities that allow the patient to live according to his/her 
values and incorporation of the activities into the patient’s daily schedule. At the end of each 
week, scheduling additional activities for the following week; and (4) Contracts: 
Identification of a supportive individual to facilitate completion of difficult activities.
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There is an ample evidence base supporting the efficacy of BATD in the treatment of 
depression. Across studies, it is associated with reductions in depressive symptoms27,28 
including among those with major depressive disorder. 29 Behavioral Activation treatments 
have previously been delivered successfully within primary care clinics both by mental 
health nurses30 and psychologists.31 Furthermore, BATD has shown promise in a variety of 
other health-care settings, including oncology,32,33 the Veteran’s Administration health 
system,34 and substance use treatment.35–37 A key strength of BATD is that it is simple, 
straightforward, and easily understood by patients.38
An important next step is to tailor the delivery of BATD via mHealth, toward a goal of 
dissemination in real-world settings, most notably primary care. In the remainder of this 
paper, we will describe Moodivate, a mobile application adaptation of BATD, and discuss 
considerations for utilizing Moodivate in primary care.
Moodivate: Treatment development and description
Moodivate development began with a diverse team of providers, psychologists, and app 
developers in order to ensure that psychological treatment components were faithfully 
translated to a mobile platform. We utilized an agile software development approach, which 
promotes continued collaboration across the software development lifecycle between the 
entire development team.39 Moodivate consists of the following components, each discussed 
below with accompanying screenshots: (1) psychoeducation, (2) development of 
individualized values, (3) generation of activities consistent with each value, (4) scheduling 
and completing activities, (5) eliciting social support to help complete difficult activities, (6) 
ratings of daily mood, and (7) reinforcement for treatment utilization.
Psychoeducation
To provide BATD rationale, users complete a psychoeducational interactive tutorial 
illustrating the connection between thoughts, feelings, and behavior. This treatment rationale 
ultimately highlights that Moodivate will focus on increasing activity to improve mood and 
decrease the incidence of negative, depressogenic cognitions (Figure 1). Users practice 
generating values and activities and receive instruction regarding how to use the app.
Development of individualized values
Users are then taken to the “Life Areas” screen, where they can select from five life areas 
(Relationships, Daily Responsibilities, Recreation, Career and Education, and Health) in 
which to develop values (Figure 2). A value can be defined as an ideal, quality, or strong 
belief in a certain way of living. For example, within the life area of relationships, a user 
might generate a value of “Be a trustworthy friend.” This value-driven framework helps to 
ensure that selected activities will be positively reinforced over time, by virtue of being 
connected to what the user values as important.26 Ideally, users should generate several 
unique values within each life area.
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Generation of activities consistent with each value
Values are then used as a framework for generating aligning activities. Within each life area, 
users add activities within each value (Figure 3). For the user who generated the value of 
“Be a trustworthy friend” within the life area of relationships, possible activities might 
include going to dinner with a friend once a week or calling a friend for 20 minutes twice a 
week. Importantly, activities should be observable (i.e., someone else can see the user 
complete the activity) and measurable (i.e., can be scheduled into a finite period of time on a 
calendar). Thus, an activity such as “Think positively” would not be an appropriate activity 
because it is neither observable nor measurable. Users will generate several activities for 
each value.
Scheduling and completing activities
Once a user has generated activities across numerous values, the user then proceeds to 
schedule these activities via the Calendar screen (Figure 4). Here, the user will schedule 
value-driven activities, monitor already occurring activities, and identify when an activity 
has been completed. Color coding distinguishes activities in the past or upcoming, and users 
can rate how enjoyable and important each activity was. After completing an activity, the 
patient receives reinforcement for completing the activity (e.g., “Nice going, you did it!”). 
Ideally, the calendar screen should be utilized daily in order to track ongoing activities and 
monitor treatment progress.
Eliciting social support to help complete difficult activities
Sometimes activities are difficult for a user to complete on his/her own, and it can be useful 
to solicit help from others. For example, a user might schedule in an activity to go grocery 
shopping weekly, but might not have access to reliable transportation. In this case, it would 
be useful for the user to enlist social support to complete that activity. In Moodivate, 
enlisting social support is referred to as an “Assist” (shown as a life preserver icon) that 
allows the user to identify another individual(s) who can help (Figure 5). The user then has 
the option to schedule a time to ask that person for help. Assists can also be developed if an 
activity has been scheduled, but not completed three times. In this instance, a pop-up will 
appear on the calendar screen with the message “It seems like you have scheduled this 
activity a few times but have been unable to complete it. Do you want to create an assist?”
Ratings of daily mood
Moodivate users can track daily mood in order to ultimately track treatment progress. 
Calendar prompts trigger users to rate their mood each day on a scale of 1 (terrible) to 5 
(great). Within the User Info tab, the patient can view a graph of fluctuations in daily mood 
overlaid upon a graph of number of completed activities, illustrating the connection between 
activity and mood (Figure 6).
Reinforcement for treatment utilization
Moodivate users are reinforced for treatment engagement via badges. When a user earns a 
badge, a pop-up displays on the screen congratulating the user and explaining why the user 
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earned that badge (Figure 7). A user can view all of the badges he/she has earned as well as 
the badges he/she has yet to earn on the User Info page.
Moodivate evaluation
Although BATD has a strong base of empirical support, BATD delivered within a mobile 
app, and specifically Moodivate, has not been tested. Early evaluation is now underway. Our 
team is conducting a clinical trial evaluation of Moodivate among patients with moderate 
symptoms of depression identified within the family medicine practice setting. Patients are 
being randomized to one of three arms: Moodivate, an active control mobile app, or 
treatment as usual. All patients, regardless of treatment group, receive standard patient 
education materials about depression and providers deliver depression treatment as they 
normally would. If randomized to an app condition, participants are asked to utilize their app 
at least once per day. All participants complete weekly assessments of depressive symptoms, 
affect, and other related constructs (e.g., anhedonia, activation, and anxiety). App utilization 
is assessed via analytics data and participant self-report, including qualitative feedback 
related to participant impressions of each mobile app. Our initial goals within this pilot study 
are to examine treatment acceptability and feasibility as well as change in depressive 
symptoms over a brief (two-month) period. Based on participant feedback, we plan to refine 
Moodivate in order to improve treatment acceptability and ease of use.
This pilot RCT of Moodivate will provide us with preliminary data regarding treatment 
efficacy, but will also leave many questions unanswered. As pharmacotherapy is a first line 
treatment for depression in primary care, an important follow-up study should examine 
Moodivate efficacy when delivered alone versus in combination with pharmacotherapy. In 
light of previous studies which have demonstrated that combination psychotherapy and 
pharmacotherapy delivered via primary care is associated with significantly greater effect 
than either treatment delivered alone,29,40 one might expect that similar results would be 
found with Moodivate, but this is yet unknown.
Potential dissemination of Moodivate within primary care
It is important to note that even though the evidence base for Moodivate is in its infancy, 
BATD, the treatment on which Moodivate is based, has extensive support. Extension of 
BATD into mHealth platforms is the logical next step. While we anticipate strong treatment 
effects from Moodivate, even modest effects would have very large impact with expanded 
reach as might be expected with dissemination into primary care. Thus, the remainder of this 
paper presents some of the major issues to consider for this dissemination.
Assessing treatment response
Effective management of depression within primary care begins with evidence-based 
screening/assessment. There are many options for screening and thus not fully addressed 
herein [see Williams et al.41 for a comprehensive review of available instruments for 
screening for depresison in primary care]. Per Institute for Clinical Systems Improvement 
(ICSI) guidelines,42 patients with mild depressive symptoms should be provided with 
support, educated to contact their physician if symptoms worsen, and scheduled for a return 
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appointment within one month. Patients with moderate or greater depressive symptoms 
should receive more intensive treatment. For these patients, Moodivate may be applicable as 
an adjunct treatment. Patients with moderate or severe depression, or those who endorse 
suicidality likely should not utilize Moodivate as a monotherapy. In these instances, 
combining Moodivate with traditional psychotherapy and/or medication management may 
be appropriate. Standard risk assessment and intervention procedures should be 
implemented for patients endorsing suicidality, which may include urgent referral to crisis 
specialty health care.
At every follow-up visit, patients should recomplete a depression screening measure. This 
follow-up assessment can be compared to prior scores in order to track overall trajectory of 
depressive symptoms and determine whether alterations should be made to the treatment 
plan. Consistent with ICSI guidelines,42 treatment response can be defined as a 50% or 
greater reduction in symptoms as measured on standardized ratings scales. Partial response 
is defined as a 25%–50% reduction in symptoms. Full depression remission is defined as a 
two-month period devoid of major depressive disorder symptoms. Moodivate treatment 
duration is an important empirical question that has not yet been examined, thus treatment 
response and symptom remission may be useful indicators to determine whether treatment 
should be modified, continued, or terminated. As traditional BATD treatment typically 
occurs over 8–10 weeks,26 in our ongoing clinical trial, we encourage participants to utilize 
the app over the course of 8 weeks.
Treatment access
Moodivate is commercially available for nominal cost (<$5) on iOS platforms. Expansion to 
Android is planned for the future. Thus, in addition to symptom severity, mobile phone 
ownership, type of mobile phone, and cost are all factors that should be considered prior to 
recommending Moodivate. Regarding treatment access for the provider, Moodivate does not 
currently incorporate a provider-facing component. In the future, we plan to explore adding 
additional functionality to allow physicians to track patient progress remotely including 
receiving alerts on nonuse as well as clinical deterioration. Providers who wish to assess 
patient usage of Moodivate are encouraged to discuss Moodivate use with patients during 
follow-up appointments, including frequency of app utilization, number of values and 
activities selected, benefits/difficulties of use, and overall number of symptoms and 
functional impairment. The app could be opened and shared with the provider to review 
values, activities, mood, and assists.
Promoting treatment adherence
Prior trials of dissemination of remotely delivered computerized psychological interventions 
with primary care patients have struggled with poor treatment adherence, particularly among 
those with clinical levels of depression.43 One primary patient-reported barrier to treatment 
engagement with this mode of delivery is the need for monitoring and/or follow-up to 
support treatment completion.44 Thus, patient uptake of Moodivate will likely greatly 
depend on the advice and recommendations of their trusted medical providers. As such, in 
addition to continual symptom monitoring as discussed above, engagement from clinicians 
(or other members of the medical team) is likely also useful, if not necessary. This 
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engagement could be brief (simple recommendation) or more pronounced (download and 
introduction within clinical encounter, discussion of questions, and general 
psychoeducation), and this is left to provider discretion. At minimum, providers should 
recommend regular use of the app and follow-up at next visit.
Treatment motivation
Low motivation is a core symptom of depression that is likely to interfere with treatment 
engagement. Moodivate incorporates several features to reinforce treatment engagement and, 
by extension, motivation, including positive messages after activities are completed and 
badges which are earned for continued treatment adherence. Providers likely should also 
assess motivation for depression treatment prior to recommending Moodivate. Patients who 
endorse lower treatment motivation may benefit from other treatment approaches, such as 
Motivational Interviewing, either instead of or prior to Moodivate.
Conclusions
In sum, Moodivate is a promising mobile app adaptation of a popular evidence-based 
psychotherapy for depression. Moodivate may extend the menu of treatment options for 
primary care physicians and their patients with elevated depressive symptoms. Moodivate 
fits well into current clinical guidelines recommending thorough assessment, treatment, and 
follow-up for depression. With additional testing, focusing both on efficacy and 
effectiveness, Moodivate has the potential to improve accessibility of evidence-based 
psychotherapy for patients in need who do not utilize traditional mental health treatments.
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Life areas and values.
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Rating and tracking daily mood.
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